Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Medistim ASA is a medical technology company specializing in the development, production, servicing, leasing, and distribution of innovative devices for cardiac, vascular, and transplant surgery. Headquartered in Oslo, Norway, and founded in 1984, it leads the market in intraoperative transit time flow measurement (TTFM) and ultrasound imaging through its flagship MiraQ systems, including MiraQ Cardiac, MiraQ Vascular, and MiraQ Ultimate. These integrated platforms combine ultrasound imaging with TTFM to provide surgeons with precise, real-time insights, enabling quality verification of grafts and vessels to enhance surgical outcomes and reduce risks. Medistim also offers specialized probes like QuickFit and Vascular TTFM probes, alongside Doppler and imaging probes for detecting stenoses and intramural arteries. The company distributes third-party medical equipment in the Nordic region and operates globally across the United States, Europe, Asia, and beyond, employing around 154 people. Its business model includes capital sales, leasing, and consumables, emphasizing patient safety, clinical research backing, and sustainable practices under ISO standards. Medistim ASA plays a vital role in advancing surgical precision worldwide.
NOK 230.00
+NOK 0.00 (+0.00%)
Live · 05:22 PM
Margins and capital returns are both well above average: 28.04% operating margin, ROIC at 30.55%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 24.4% YoY with margins expanding 4.7pp.
At 27x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
26.9x earnings, 29.5x FCF. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 720M
▲ +24.4% YoY
Net Income (TTM)
NOK 156M
▲ +53.3% YoY
Op. Margin
26.96%
▲ +4.7pp YoY
ROIC
30.55%
▲ +7.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
NOK 142M
▲ +8.8% YoY
Op. Cash Flow (TTM)
NOK 184M
▲ +27.9% YoY
Net Debt
-NOK 157M
Net Cash Position
Cash & Equiv.
NOK 206M
3Y CAGR: +12.9%
3Y CAGR: +18.6%
Continue Research
At a P/E of 26.9 and a price-to-free-cash-flow of 29.5, Medistim ASA (MEDI.XOSL) trades above a two-stage DCF intrinsic value of about NOK 162.86 per share, so at NOK 230.00 the stock looks overvalued (29.2% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Medistim ASA scores 71/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 2.6%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about NOK 162.86 per share for MEDI.XOSL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around NOK 122.15. At today's NOK 230.00, that puts the stock about 29.2% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Medistim ASA scores 71 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 27.0% operating margin and a 30.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Medistim ASA pays a regular dividend of about NOK 5.99 per share per year (typically in quarterly installments), a yield of roughly 2.6% at the current price. That is a payout ratio of about 70.1% of earnings, so the dividend is covered, with less cushion. Medistim ASA has grown the dividend at roughly 19.0% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For MEDI.XOSL's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. MEDI.XOSL currently trades above its estimated intrinsic value and scores 71/100 on quality (solid). It also yields about 2.6%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.